Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival.

• DOI: 10.1200/jco.2012.30.15_suppl.7572
• Publication Date: 2020-03-11T19:18:30Z
• Authors: Martin Faehling; Robert Eckert; Torsten G. Kamp; Sabine Kuom; Werner Spengler
• Keywords: Erlotinib Hydrochloride; Progression-free survival; Afatinib

7572 Background: EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib lead to prolonged disease stabilization in some patients with advanced NSCLC. It is so far not clear how treat who progress after response erlotinib. TKI therapy beyond progression added chemotherapy, radiotherapy or best supportive care (BSC) may improve survival compared BSC alone. Methods: We retrospectively analyzed all NSCLC treated at our institutions since 2004 progressed least stable on for six months (n=41). Twenty-seven were (TKI patients), of whom 24 received and 3 afatinib. Fourteen did receive further treatment (controls). Overall (OS) from OS diagnosis lung cancer was the whole population case-control subpopulations pairs matched gender, smoking status, histology. Results: Treatment chemotherapy well tolerated no increase grade 4 toxicities. TKI-patients had a significantly longer (case control: median 21.0 vs. 3.0 months, HR 0.175) 28.5 15.3 0.335). Conclusions: In long-term responders, addition feasible limited toxicity. TKI-treatment improved TKI-free radiotherapy.